Parkinson's research readers will open an article on a company announcement about its experimental therapy joining a collaborative platform study and outlining study objectives and partnerships.
Key Takeaways
- Foresee's mirivadelgat was selected for inclusion in a Parkinson's Phase 2a platform trial
- Forty participants will be randomized 3:1, creating an effective 30 versus 30 comparison
- Study will assess CNS penetration, ALDH2 target engagement, and safety